Use of Dopaminergic Agonists for Renal Protection in the ICU
作者： P. T. Murray
DOI: 10.1007/978-1-4757-5548-0_61
关键词:
摘要: The mortality of acute renal failure is commonly 50–80% in the intensive care unit (ICU), and has not declined significantly since initial marked benefit dialysis therapy, despite numerous advances replacement technologies critical over several decades. Most ICU patients caused by either prerenal azotemia (reversible insufficiency due to hypoperfusion) or tubular necrosis (ATN). ATN results from a variety ischemic nephrotoxic insults, often additive synergistic combination. Because hypoperfusion plays role pathogenesis ATN, ‘lowdose’ dopamine used as vasodilator aiming prevent treat ICU. This chapter reviews use novel dopaminergic agonist called fenoldopam for protection
springer.com
sci-hub.st 参考文章(59)
A D Bersten, A W Holt, Vasoactive drugs and the importance of renal perfusion pressure. New Horizons-the Science and Practice of Acute Medicine. ,vol. 3, pp. 650- 661 ,(1995)
Robert M. Carey, Helmy M. Siragy, N. Virginia Ragsdale, Nancy L. Howell, Robin A. Felder, Michael J. Peach, Robert L. Chevalier, Dopamine-1 and dopamine-2 mechanisms in the control of renal function. American Journal of Hypertension. ,vol. 3, ,(1990) , 10.1093/AJH/3.6.59S
Vandana S. Mathur, Suzanne K. Swan, Lawrence J. Lambrecht, Shakeel Anjum, Jere Fellmann, Dawn McGuire, Murray Epstein, Robert R. Luther, The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects Critical Care Medicine. ,vol. 27, pp. 1832- 1837 ,(1999) , 10.1097/00003246-199909000-00021
Diane K. Jorkasky, Patricia Audet, Neil Shusterman, Bernard Ilson, Donald Dafoe, Diane Hedrich, Robert M. Stote, Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients. American Journal of Kidney Diseases. ,vol. 19, pp. 567- 572 ,(1992) , 10.1016/S0272-6386(12)80836-5
J.A. Tumlin, A. Wang, P.T. Murray, V.S. Mathur, Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. American Heart Journal. ,vol. 143, pp. 894- 903 ,(2002) , 10.1067/MHJ.2002.122118
Michael B. Murphy, Clare Murray, George D. Shorten, Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. The New England Journal of Medicine. ,vol. 345, pp. 1548- 1557 ,(2001) , 10.1056/NEJMRA010253
Greet Van den Berghe, Francis de Zegher, Anterior pituitary function during critical illness and dopamine treatment Critical Care Medicine. ,vol. 24, pp. 1580- 1590 ,(1996) , 10.1097/00003246-199609000-00024
Graeme J. Duke, Juris H. Briedis, Rupert A. Weaer, Renal support in critically ill patients: Low-dose dopamine or low-dose dobutamine? Critical Care Medicine. ,vol. 22, pp. 1919- 1925 ,(1994) , 10.1097/00003246-199412000-00006
Samuel N. Heyman, Mayer Brezis, Franklin H. Epstein, Katherine Spokes, Patricio Silva, Seymour Rosen, Early renal medullary hypoxic injury from radiocontrast and indomethacin Kidney International. ,vol. 40, pp. 632- 642 ,(1991) , 10.1038/KI.1991.255
Neil H. Shusterman, William J. Elliott, William B. White, Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function The American Journal of Medicine. ,vol. 95, pp. 161- 168 ,(1993) , 10.1016/0002-9343(93)90256-O